<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31929">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096718</url>
  </required_header>
  <id_info>
    <org_study_id>1200.216</org_study_id>
    <secondary_id>2013-004825-98</secondary_id>
    <nct_id>NCT02096718</nct_id>
  </id_info>
  <brief_title>Afatinib in Subjects With Kidney Dysfunction</brief_title>
  <official_title>Pharmacokinetics, Safety and Tolerability After Single Dose Administration of Afatinib in Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study in Matched-group Design)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the current study is to investigate the influence of moderate to
      severe renal impairment on the pharmacokinetics and safety of a single dose afatinib in
      comparison to a control group with normal renal function.

      The assessment of safety and tolerability will be an additional objective of this trial and
      will be evaluated by descriptive statistics.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)</measure>
    <time_frame>312 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>312 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>312 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Afatinib in moderate renal impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Afatinib in moderate renal impaired subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afatinib in severe renal impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Afatinib in severe renal impaired subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afatinib in healthy subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single Dose Afatinib in healthy subjects matched by gender, race, age and BMI to moderate and severe renal impaired subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib healthy</intervention_name>
    <arm_group_label>Afatinib in healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib severe renally impaired</intervention_name>
    <arm_group_label>Afatinib in severe renal impaired</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib moderate renally impaired</intervention_name>
    <arm_group_label>Afatinib in moderate renal impaired</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Despite renal impairment (group 1 and 2) healthy males or females according to the
             investigators assessment, as based on the following criteria: a complete medical
             history including a physical examination, vital signs (Blood Pressure (BP), Pulse
             Rate (PR)), 12-lead Electrogardiogram (ECG), and clinical laboratory tests.

          -  Glomerular filtration rate (GFR), estimated according to:

             -- MDRD (Modification of Diet in Renal Disease)-formula:

               -  eGFR (estimated Glomerular Filtration Rate) [ml/min/1.73m²]= 175 x Serum
                  Creatinine-1.154 x age-0.203 (if male)

               -  eGFR[ml/min/1.73m²]= 175 x Serum Creatinine-1.154 x age-0.203 x 0.742 (if
                  female)

               -  30 to 59 mL/min for moderate renal impairment group 1

               -  15 to 29 mL/min for severe renal impairment group 2

               -  = 90 mL/min for healthy volunteers group 3

          -  Age =18 and =79 years

        Exclusion criteria:

          -  Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate
             (PR) and Electrocardiogram (ECG)) deviating from normal and of clinical relevance,
             e.g. repeated measurement of systolic blood pressure &lt; 90 mmHg (millimeter of
             mercury) or &gt; 140 mmHg, diastolic blood pressure &lt; 50 mmHg or &gt; 90 mmHg, repeated
             measurement of pulse rate &lt; 45 bpm (beats per minute) or &gt; 90 bpm.

          -  Any evidence of a clinically relevant concomitant disease.

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, dermatological or hormonal disorders.

          -  Relevant gastrointestinal tract surgery (except appendectomy).

          -  Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric
             disorders or neurological disorders.

          -  History of photosensitivity or recurrent rash.

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1200.216.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
